Convertibles Calendar: Ascendis Pharma on tap

March 24

ASCENDIS PHARMA A/S:

• $500 million six-year convertible notes

• Greenshoe of $75 million

• Coupon of 2% to 2.5% and initial conversion premium of 37.5% to 42.5%

• Bookrunners J.P. Morgan Securities LLC and Evercore Inc.

• Non-callable until April 7, 2025 and then subject to a 130% hurdle

• Rule 144A

• Repurchase up to 1 million ADSs, support the commercialization of products in the pipeline and general corporate purposes

• Copenhagen-based biopharmaceutical company

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.